West Sussex-based biotech concern Veryan Med, which specialises in addressing vascular disease, has received  £2.5 million in a further funding round from Imperial Innovations.

West Sussex-based biotech concern Veryan Med, which specialises in addressing vascular disease, has received £2.5 million in a further funding round from Imperial Innovations.

Susan Searle, chief executive of Imperial Innovations, says: ‘Imperial Innovations continues to take the lead in supporting Veryan, one of our core portfolio companies.

‘We are in the enviable position of having the cash resources, infrastructure and people needed to turn science into value. Our further investment in Veryan today takes it a step closer to market.’

Veryan’s own management team has also invested in the funding round. Separate to this round, Veryan has received investments totalling approximately £3 million to date.

This is Imperial Innovations’ fourth investment so far this year.